Effect of Community-Acquired Pneumonia on Acute Exacerbation of Chronic Obstructive Pulmonary Disease

References

• Müllerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106(8):1124–1133. DOI:10.1016/j.rmed.2012.04.008
   PubMed Web of Science ®Google Scholar
• Gutierrez P, Closa D, Piñer R, et al. Macrophage activation in exacerbated COPD with and without community-acquired pneumonia. Eur Respir J. 2010;36(2):285–291. DOI:10.1183/09031936.00118909
   PubMed Web of Science ®Google Scholar
• Hunter LC, Lee RJ, Butcher I, et al. Patient characteristics associated with risk of first hospital admission and readmission for acute exacerbation of chronic obstructive pulmonary disease (COPD) following primary care COPD diagnosis: a cohort study using linked electronic patient records. BMJ Open. 2016;6(1):e009121–9. DOI:10.1136/bmjopen-2015-009121
   PubMed Web of Science ®Google Scholar
• Hogea SP, Tudorache E, Fildan AP, et al. Risk factors of chronic obstructive pulmonary disease exacerbations. Clin Respir J. 2020;14(3):183–197. DOI:10.1111/crj.13129
   PubMed Web of Science ®Google Scholar
• Schembri S, Anderson W, Morant S, et al. A predictive model of hospitalisation and death from chronic obstructive pulmonary disease. Respir Med. 2009;103(10):1461–1467. DOI:10.1016/j.rmed.2009.04.021
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Kunisaki KM, Strand MJ, COPDGene Investigators, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(3):324–330. DOI:10.1164/rccm.201605-1014OC
   PubMed Web of Science ®Google Scholar
• Müllerová H, Shukla A, Hawkins A, et al. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014;4(12):e006171. DOI:10.1136/bmjopen-2014-006171
   PubMed Web of Science ®Google Scholar
• Cardoso J, Coelho R, Rocha C, et al. Prediction of severe exacerbations and mortality in COPD: the role of exacerbation history and inspiratory capacity/total lung capacity ratio. Int J Chron Obstruct Pulmon Dis. 2018;13:1105–1113. DOI:10.2147/COPD.S155848
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(3):CD010115.
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh S, Nordestgaard BG, Lange P, et al. Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD. Eur Respir J. 2018;51(5):1800120. DOI:10.1183/13993003.00120-2018
   PubMed Web of Science ®Google Scholar
• Huerta A, Crisafulli E, Menéndez R, et al. Pneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristics. Chest. 2013;144(4):1134–1142. DOI:10.1378/chest.13-0488
   PubMed Web of Science ®Google Scholar
• Søgaard M, Madsen M, Løkke A, et al. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. Int J Chron Obstruct Pulmon Dis. 2016;11:445–465.
   PubMed Web of Science ®Google Scholar
• Steer J, Norman EM, Afolabi OA, et al. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax. 2012;67(2):117–121. DOI:10.1136/thoraxjnl-2011-200332
   PubMed Web of Science ®Google Scholar
• Andreassen SL, Liaaen ED, Stenfors N, et al. Impact of pneumonia on hospitalizations due to acute exacerbations of COPD. Clin Respir J. 2014;8(1):93–99. DOI:10.1111/crj.12043
   PubMed Web of Science ®Google Scholar
• Claessens YE, Debray MP, Tubach F, et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med. 2015;192(8):974–982. DOI:10.1164/rccm.201501-0017OC
   PubMed Web of Science ®Google Scholar
• Yu S, Fang Q, Li Y. Independent factors associated with pneumonia among hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease. Medicine (Baltimore). 2018;97(42):e12844. DOI:10.1097/MD.0000000000012844
   PubMed Web of Science ®Google Scholar
• Boixeda R, Bacca S, Elias L, et al. Pneumonia as comorbidity in chronic obstructive pulmonary disease (COPD). Differences between acute exacerbation of COPD and pneumonia in patients with COPD. Arch Bronconeumol. 2014;50(12):514–520. DOI:10.1016/j.arbres.2014.02.001
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Miravitlles M, Celli BR, et al. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial. Respir Res. 2018;19(1):196. DOI:10.1186/s12931-018-0874-0
   PubMedGoogle Scholar
• Dransfield MT, Crim C, Criner GJ, et al. Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT. Ann Am Thorac Soc. 2021;18(5):788–798. DOI:10.1513/AnnalsATS.202002-096OC
   PubMed Web of Science ®Google Scholar
• Titova E, Christensen A, Henriksen AH, et al. Comparison of procalcitonin, C-reactive protein, white blood cell count and clinical status in diagnosing pneumonia in patients hospitalized with acute exacerbations of COPD: a prospective observational study. Chron Respir Dis. 2019;16:1479972318769762. DOI:10.1177/1479972318769762
   Web of Science ®Google Scholar
• Taylor AE, Finney-Hayward TK, Quint JK, et al. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J. 2010;35(5):1039–1047. DOI:10.1183/09031936.00036709
   PubMed Web of Science ®Google Scholar
• Tanriverdi H, Örnek T, Erboy F, et al. Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD. Wien Klin Wochenschr. 2015;127(19–20):756–763. DOI:10.1007/s00508-014-0690-6
   PubMed Web of Science ®Google Scholar
• Lu Z, Cheng Y, Tu X, et al. Community-acquired pneumonia and survival of critically ill acute exacerbation of COPD patients in respiratory intensive care units. COPD. 2016;11:1867–1872. DOI:10.2147/COPD.S113510
   Google Scholar
• Shin B, Kim SH, Yong SJ, et al. Early readmission and mortality in acute exacerbation of chronic obstructive pulmonary disease with community-acquired pneumonia. Chron Respir Dis. 2019;16:147997231880948. DOI:10.1177/1479972318809480
   Web of Science ®Google Scholar
• Stenfors N, Liaaen ED, Henriksen AH. No difference in long term survival in patients hospitalized for pneumonic versus non-pneumonic acute exacerbations of COPD. Clin Respir J. 2018;12(3):1305–1306. DOI:10.1111/crj.12636
   PubMed Web of Science ®Google Scholar
• Myint PK, Lowe D, Stone RA, et al. U.K. National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary disease exacerbations. Respiration. 2011;82(4):320–327. DOI:10.1159/000327203
   PubMed Web of Science ®Google Scholar
• Kim HC, Choi SH, Huh JW, et al. Different pattern of viral infections and clinical outcomes in patient with acute exacerbation of chronic obstructive pulmonary disease and chronic obstructive pulmonary disease with pneumonia. J Med Virol. 2016;88(12):2092–2099. DOI:10.1002/jmv.24577
   PubMed Web of Science ®Google Scholar
• Sharafkhaneh A, Spiegelman AM, Main K, et al. Mortality in patients admitted for concurrent COPD exacerbation and pneumonia. COPD. 2017;14(1):23–29. DOI:10.1080/15412555.2016.1220513
   PubMedGoogle Scholar
• Mannino DM, Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir Med. 2009;103(2):224–229. DOI:10.1016/j.rmed.2008.09.005
   PubMed Web of Science ®Google Scholar
• Juthani-Mehta M, De Rekeneire N, Allore H, Health ABC Study, et al. Modifiable risk factors for pneumonia requiring hospitalization of community-dwelling older adults: the Health, Aging, and Body Composition Study. J Am Geriatr Soc. 2013;61(7):1111–1118. DOI:10.1111/jgs.12325
   PubMed Web of Science ®Google Scholar
• Labaki WW, Xia M, Murray S, et al. NT-proBNP in Stable COPD and future exacerbation risk: analysis of the SPIROMICS cohort. Respir Med. 2018;140:87–93. DOI:10.1016/j.rmed.2018.06.005
   PubMed Web of Science ®Google Scholar
• Stolz D, Breidthardt T, Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest. 2008;133(5):1088–1094. DOI:10.1378/chest.07-1959
   PubMed Web of Science ®Google Scholar
• Medina AM, Marteles MS, Saiz EB, et al. Prognostic utility of NT-proBNP in acute exacerbations of chronic pulmonary diseases. Eur J Intern Med. 2011;22(2):167–171. DOI:10.1016/j.ejim.2010.12.002
   PubMed Web of Science ®Google Scholar
• Marcun R, Sustic A, Brguljan PM, et al. Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. Int J Cardiol. 2012;161(3):156–159. DOI:10.1016/j.ijcard.2012.05.044
   PubMed Web of Science ®Google Scholar
• Hoiseth AD, Omland T, Hagve TA, et al. NT-proBNP independently predicts long term mortality after acute exacerbation of COPD – a prospective cohort study. Respir Res. 2012;13(1):97. DOI:10.1186/1465-9921-13-97
   PubMedGoogle Scholar
• Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66(9):764–768. DOI:10.1136/thx.2010.155333
   PubMed Web of Science ®Google Scholar